<?xml version="1.0" encoding="UTF-8"?>
<p>Based on in silico analysis, the drug likeness score of CBDA predicted it as possible G protein-coupled receptors (GPCRs) ligands, ion channel modulators, kinase inhibitors, nuclear receptor ligands, and protease inhibitors with moderately active in all bioactive scores [
 <xref rid="B101-ijms-21-09049" ref-type="bibr">101</xref>]. According to recent studies CBDA has anticancer activity [
 <xref rid="B63-ijms-21-09049" ref-type="bibr">63</xref>,
 <xref rid="B64-ijms-21-09049" ref-type="bibr">64</xref>,
 <xref rid="B65-ijms-21-09049" ref-type="bibr">65</xref>,
 <xref rid="B66-ijms-21-09049" ref-type="bibr">66</xref>], anti-inflammatory activity [
 <xref rid="B67-ijms-21-09049" ref-type="bibr">67</xref>,
 <xref rid="B68-ijms-21-09049" ref-type="bibr">68</xref>,
 <xref rid="B69-ijms-21-09049" ref-type="bibr">69</xref>], antiemetic effect [
 <xref rid="B70-ijms-21-09049" ref-type="bibr">70</xref>,
 <xref rid="B71-ijms-21-09049" ref-type="bibr">71</xref>], and anticonvulsant effect [
 <xref rid="B72-ijms-21-09049" ref-type="bibr">72</xref>]. Due to its pharmacological property (
 <xref rid="ijms-21-09049-t002" ref-type="table">Table 2</xref>), it is getting more and more attention.
</p>
